Dr Peter Connick
Supervised by Dr Siddharthan Chandran
Funded via the MRC Experimental Medicine programme, I am coordinating a phase I/IIA clinical trial of autologous adult human bone marrow derived mesenchymal stromal cells in multiple sclerosis (MSCIMS).
Developing treatments to prevent or repair axonal loss - the primary correlate of clinical disability - is a key priority for MS research. MSCIMS will begin to test one such candidate therapy. In addition, the development of a clinical science methodologies and research protocols will provide a long-term platform for the wider testing of cellular and generic putative repair therapies in MS and other neurodegenerative diseases.
mesenchymal stromal cells
Magnetic resonance imaging (MRI)
Thomas Bak Web: http://www.psy.ed.ac.uk/people/...
David Miller Web: http://www.ion.ucl.ac.uk/researc...
Jan Brinchmann Web: http://www.stemcell.no/groups/...
Connick P, Kolappan M, Bak TH, Chandran S (2011), “Verbal fluency as a rapid screening test for cognitive impairment in progressive multiple sclerosis.” J Neurol Neurosurg Psychiatry Details
Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He XL, Richardson K, Barber K, Webber DJ, Wheeler-Kingshott CA, Tozer DJ, Samson RS, Thomas DL, Du MQ, Luan SL, Michell AW, Altmann DR, Thompson AJ, Miller DH, Compston A, Chandran S (2011), “The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.” Trials 12:62 Details
Connick P, Patani R, Chandran S (2011), “Stem cells as a resource for regenerative neurology.” Pract Neurol 11(1):29-36 Details